Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 11, 2007

Nabi Divests Biologics Unit for $185M to Biotest

  • Nabi Biopharmaceuticals is divesting its Nabi Biologics strategic business unit (SBU) to Biotest Pharmaceuticals for $185 million.

    Biotest will thus acquire the Biologics SBU’s products including Nabi-HB®, a marketed therapy indicated to prevent hepatitis B infection. It will also gain all the plasma business assets such as the plasma protein production plant and nine FDA-certified plasma collection centers across the U.S.

    “With the acquisition of Nabi Biologics, we have found the ideal complement for our European plasma protein business and have become a global player in the industry,” comments Gregor Schulz, chairman of the management board of Biotest.

    After the closing of the transaction, Nabi Biopharmaceuticals will operate its Pharmaceuticals SBU from its existing Rockville, MD facility, which will become its new headquarters.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »